Huda Y. Zoghbi - 13 Oct 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/** Huda Y. Zoghbi
Issuer symbol
REGN
Transactions as of
13 Oct 2023
Net transactions value
-$458,080
Form type
4
Filing time
17 Oct 2023, 16:06:37 UTC
Previous filing
05 Jan 2023
Next filing
04 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $391,920 +1,000 +80% $391.92 2,247 13 Oct 2023 Direct F1
transaction REGN Common Stock Sale $850,000 -1,000 -45% $850.00 1,247 13 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,000 -47% $0.000000 1,117 13 Oct 2023 Common Stock 1,000 $391.92 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.
F2 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.